MedPath

A CLINICAL STUDY TO FIND THE EFFECT OF TWO AYURVEDIC DRUGS AMRITA GUGGULU AND RASNADASAMOOLA KWATHAM IN REDUCING DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

Phase 3
Not yet recruiting
Conditions
Inflammatory polyarthropathies. Ayurveda Condition: VATARAKTAM, (2) ICD-10 Condition: M05||Rheumatoid arthritis with rheumatoid factor. Ayurveda Condition: VATARAKTAM,
Registration Number
CTRI/2021/04/032954
Lead Sponsor
Dr Pravith N K
Brief Summary

To know the effect of Amrita Guggulu and Rasnadasamoola kwatham in the management of reducing the disease activity scale and blood parameters in Rheumatoid Arthritis.The null hypothesis is Amrita Guggulu and Rasnadasamoola kwatham is not effective in Rheumatoid Arthritis and the alternate hypothesis is Amrita Guggulu and Rasnadasamoola kwatham is effective in Rheumatoid Arthritis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Male and Female patients of age group 30-60 years, diagnosed as Rheumatoid Arthritis by satisfying the 2010 ACR diagnostic criteria.

Exclusion Criteria
  • 1.Patients with major structural deformity as a complication of Rheumatoid Arthritis.
  • 2.Patients with known history of major liver disorders, lung disorders and cardiac illness.
  • 3.Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
•Changes in DAS 28 scaleat baseline, 30 days
•Changes in grading of tenderness, morning stiffness.at baseline, 30 days
•Changes in lab investigations for estimation of ESR, RA factor.at baseline, 30 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Government Ayurveda college Thiruvananthapuram

🇮🇳

Thiruvananthapuram, KERALA, India

Government Ayurveda college Thiruvananthapuram
🇮🇳Thiruvananthapuram, KERALA, India
Anupama A S
Principal investigator
7403281992
anupama.ayurvedam@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.